Cargando…

Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy?

Compliance with treatment guidelines is essential to achieve successful outcomes in tuberculosis patients. Thus, we assessed if multidrug-resistant tuberculosis treatment practices from 2012–2018 in Uzbekistan were compliant with national guidelines in terms of regimens prescribed, weight-based drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Usmanova, Ruzilya, Parpieva, Nargiza, Davtyan, Hayk, Denisiuk, Olga, Gadoev, Jamshid, Alaverdyan, Sevak, Dumchev, Kostyantyn, Liverko, Irina, Abdusamatova, Barno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070610/
https://www.ncbi.nlm.nih.gov/pubmed/33921547
http://dx.doi.org/10.3390/ijerph18084071
_version_ 1783683510398091264
author Usmanova, Ruzilya
Parpieva, Nargiza
Davtyan, Hayk
Denisiuk, Olga
Gadoev, Jamshid
Alaverdyan, Sevak
Dumchev, Kostyantyn
Liverko, Irina
Abdusamatova, Barno
author_facet Usmanova, Ruzilya
Parpieva, Nargiza
Davtyan, Hayk
Denisiuk, Olga
Gadoev, Jamshid
Alaverdyan, Sevak
Dumchev, Kostyantyn
Liverko, Irina
Abdusamatova, Barno
author_sort Usmanova, Ruzilya
collection PubMed
description Compliance with treatment guidelines is essential to achieve successful outcomes in tuberculosis patients. Thus, we assessed if multidrug-resistant tuberculosis treatment practices from 2012–2018 in Uzbekistan were compliant with national guidelines in terms of regimens prescribed, weight-based drug dosages used, and documentation of treatment changes (such as prolongation of intensive phase, change of drugs, and their reasons) in the treatment card and Consilium form. A total of 1481 patients were included. Of them, only 25% received standardized regimens as per guidelines and the remaining received individualized regimens. There was an increasing trend in using standardized regimens from 2% in 2012 to 44% in 2018. Compliance to recommended weight-based drug dosages was observed in 85% of the patients during the intensive phase and 84% in the continuation phase—ranged 71–91% over the years. Prolongation of the intensive phase was done in 42% of patients. The treatment was changed in 44% of patients during the intensive phase and 34% of patients during the continuation phase. The documentation of treatment changes was suboptimal (42–75%) during the initial years (2012–2014); however, it improved significantly during later years (86–100%). Future research should explore reasons for non-compliance so that the quality of patient care can be improved.
format Online
Article
Text
id pubmed-8070610
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80706102021-04-26 Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy? Usmanova, Ruzilya Parpieva, Nargiza Davtyan, Hayk Denisiuk, Olga Gadoev, Jamshid Alaverdyan, Sevak Dumchev, Kostyantyn Liverko, Irina Abdusamatova, Barno Int J Environ Res Public Health Article Compliance with treatment guidelines is essential to achieve successful outcomes in tuberculosis patients. Thus, we assessed if multidrug-resistant tuberculosis treatment practices from 2012–2018 in Uzbekistan were compliant with national guidelines in terms of regimens prescribed, weight-based drug dosages used, and documentation of treatment changes (such as prolongation of intensive phase, change of drugs, and their reasons) in the treatment card and Consilium form. A total of 1481 patients were included. Of them, only 25% received standardized regimens as per guidelines and the remaining received individualized regimens. There was an increasing trend in using standardized regimens from 2% in 2012 to 44% in 2018. Compliance to recommended weight-based drug dosages was observed in 85% of the patients during the intensive phase and 84% in the continuation phase—ranged 71–91% over the years. Prolongation of the intensive phase was done in 42% of patients. The treatment was changed in 44% of patients during the intensive phase and 34% of patients during the continuation phase. The documentation of treatment changes was suboptimal (42–75%) during the initial years (2012–2014); however, it improved significantly during later years (86–100%). Future research should explore reasons for non-compliance so that the quality of patient care can be improved. MDPI 2021-04-12 /pmc/articles/PMC8070610/ /pubmed/33921547 http://dx.doi.org/10.3390/ijerph18084071 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Usmanova, Ruzilya
Parpieva, Nargiza
Davtyan, Hayk
Denisiuk, Olga
Gadoev, Jamshid
Alaverdyan, Sevak
Dumchev, Kostyantyn
Liverko, Irina
Abdusamatova, Barno
Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy?
title Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy?
title_full Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy?
title_fullStr Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy?
title_full_unstemmed Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy?
title_short Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy?
title_sort treatment compliance of multidrug resistant tuberculosis in uzbekistan: does practice follow policy?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070610/
https://www.ncbi.nlm.nih.gov/pubmed/33921547
http://dx.doi.org/10.3390/ijerph18084071
work_keys_str_mv AT usmanovaruzilya treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy
AT parpievanargiza treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy
AT davtyanhayk treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy
AT denisiukolga treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy
AT gadoevjamshid treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy
AT alaverdyansevak treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy
AT dumchevkostyantyn treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy
AT liverkoirina treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy
AT abdusamatovabarno treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy